The addition of nedocromil sodium to maintenance therapy in the management of patients with bronchial asthma.
The addition of nedocromil sodium to maintenance asthma therapy was investigated in a 12-week double-blind group comparative trial. Maintenance therapy consisted of inhaled corticosteroid and inhaled bronchodilator; oral bronchodilator usage at constant dose was allowed but sodium cromoglycate was forbidden. Compared with placebo, the nedocromil sodium group showed greater improvement in severity of asthma and changes in lung function assessed at clinic visits, and in night-time asthma, morning tightness and PEFR recorded on diary cards. The nedocromil sodium group also showed a reduction in the diurnal variation of PEFR.